Safety of mTOR inhibitors in breast cancer.

about

Everolimus Plus Exemestane in Advanced Breast Cancer: Safety Results of the BALLET Study on Patients Previously Treated Without and with Chemotherapy in the Metastatic Setting.

P2860

Q38825756-58917C8F-A17A-4FFB-AA2B-426F32CFD7E7

P2860

Safety of mTOR inhibitors in breast cancer.

Item

http://www.wikidata.org/entity/Q38841039

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Safety of mTOR inhibitors in breast cancer.

@en

type

Item

label

Safety of mTOR inhibitors in breast cancer.

@en

prefLabel

Safety of mTOR inhibitors in breast cancer.

@en

P1476

Safety of mTOR inhibitors in breast cancer.

@en

P2093

Bohuslav Melichar

http://www.w3.org/2001/XMLSchema#string

Denisa Vitásková

http://www.w3.org/2001/XMLSchema#string

Hana Študentová

http://www.w3.org/2001/XMLSchema#string

P2860

Dosing and Safety Implications for Oncologists When Administering Everolimus to Patients With Hormone Receptor-Positive Breast Cancer

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.

Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial.

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer

Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer.

Neoadjuvant chemotherapy with paclitaxel and everolimus in breast cancer patients with non-responsive tumours to epirubicin/cyclophosphamide (EC) ± bevacizumab - results of the randomised GeparQuinto study (GBG 44).

P304

1075-1085

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

review article

P356

10.1080/14740338.2016.1192604

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-05-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27210004

http://www.w3.org/2001/XMLSchema#string

Safety of mTOR inhibitors in breast cancer.

about

P2860

P2860

Safety of mTOR inhibitors in breast cancer.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698